26th October 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Dr. Reddy's, Cipla and Aurobindo pharma recalls products from US market

According to the enforcement report by the US FDA, Dr Reddy’s Laboratories is recalling 2,838 ampules of Phytonadione Injectable Emulsion, Cipla is recalling 9,041 cartons of Arformoterol Tartrate Inhalation Solution, and Aurobindo Pharma is recalling 88,080 vials of Tranexamic acid injection.

Piramal Pharma to invest funds in expansions and acquisitions

In a recent interview, Piramal pharma’s chairperson Nandini Piramal mentioned that the company is going to focus on the sale-up of its operations and margin growth. Moreover, they are planning on spending ₹1,200 crore of capital expenditure in the next 12-18 months for the same.

Indonesia may initiate lawsuit for pharma firms over rise in children AKI deaths

On Monday, Indonesian food and drug authority stated that they will sue the two pharma firms that made the products that were possibly responsible for causing AKI (Acute Kidney Injury) that lead to 141 children (mostly under the age of 5) deaths.

Alembic Pharma Bioequivalence unit finishes US FDA inspection with no observations

The vertically integrated pharmaceutical research and development company on Tuesday, announced that its bioequivalence facility in Vadodara has completed US FDA (United States Food and Drug Administration) inspection without receiving any observations.

European pharma companies demand longer patents to invest in new antibiotics

As the antibiotic resistance increases in europe, it demands for new antibiotics. The Pharma companies are arguing on the fact that the research and development process is expensive and thus to invest in that they will need an extension on their exclusivity of the patents that they already hold for other more in-demand drugs.

Novartis to continue generic drug supply despite increasing energy costs

Novartis mentioned that its generic drugs division Sandoz will continue to manufacture and market drugs to all of its European markets and also all over the world as they can manage the energy cost surge with efficiency measures.

Biogen lifts profit vision on heavy cost cuts, more data on Alzheimer's drug crucial

As the costs more than halved, Biogen increased its annual profit forcast for the second straight quarter. The shares observed a hike of 2% as costs and expenses fell 54.3 per cent to $1.14 billion and the company now predicted the earning of $16.50 and $17.15 per share as compared to early forecast of $15.25 to $16.75.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?